Literature DB >> 9561905

A framework for understanding and responding to the psychosocial needs of children with Langerhans cell histiocytosis and their families.

S Simms1, N J Warner.   

Abstract

This article presents a five-point framework to help health-care providers understand and manage important psychosocial issues related to Langerhans cell histiocytosis (LCH). It entails frank and open discussions with patients and their families of how the disease can affect them individually and collectively. Each point is explained and then applied to two different cases. The framework is applicable to all chronic pediatric diseases, but is particularly relevant for rare conditions with unknown etiologies such as LCH.

Entities:  

Mesh:

Year:  1998        PMID: 9561905     DOI: 10.1016/s0889-8588(05)70515-3

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  Functional capacity and body mass index in patients with sellar masses--cross-sectional study on 403 patients diagnosed during childhood and adolescence.

Authors:  Hermann L Müller; Ursel Gebhardt; Andreas Faldum; Angela Emser; Nicole Etavard-Gorris; Reinhard Kolb; Niels Sörensen
Journal:  Childs Nerv Syst       Date:  2005-05-12       Impact factor: 1.475

2.  Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.

Authors:  Georgi Iskrov; Itziar Astigarraga; Rumen Stefanov; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Arrigo Schieppati; Domenica Taruscio; Márta Péntek; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-04

3.  Staff engagement during complex pediatric medical care: the role of patient, family, and treatment variables.

Authors:  Lisa J Meltzer; Elizabeth Steinmiller; Steve Simms; Michael Grossman; Yuelin Li
Journal:  Patient Educ Couns       Date:  2009-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.